Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study.

作者： S J Isakoff , D Wang , M Campone , A Calles , E Leip

关键词:

摘要: Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study

参考文章(52)

Justin M. Summy, Src family kinases in tumor progression and metastasis Cancer and Metastasis Reviews. ,vol. 22, pp. 337- 358 ,(2003) , 10.1023/A:1023772912750

Joanne L. Blum, Stephen E. Jones, Aman U. Buzdar, Patricia Mucci LoRusso, Irene Kuter, Charles Vogel, Bruno Osterwalder, Hans-Ulrich Burger, Cheryl Stoner Brown, Tom Griffin, Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer Journal of Clinical Oncology. ,vol. 17, pp. 485- 493 ,(1999) , 10.1200/JCO.1999.17.2.485

Paolo Ceppi, Ida Rapa, Marco Lo Iacono, Luisella Righi, Jessica Giorcelli, Marisa Pautasso, Andrea Billè, Francesco Ardissone, Mauro Papotti, Giorgio V. Scagliotti, Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer International Journal of Cancer. ,vol. 130, pp. 1777- 1786 ,(2012) , 10.1002/IJC.26188

P. Fumoleau, R. Largillier, C. Clippe, V. Dièras, H. Orfeuvre, T. Lesimple, S. Culine, B. Audhuy, D. Serin, H. Curé, E. Vuillemin, J.-F. Morère, F. Montestruc, Z. Mouri, M. Namer, Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. European Journal of Cancer. ,vol. 40, pp. 536- 542 ,(2004) , 10.1016/J.EJCA.2003.11.007

Renata A. Meyer, Winfried F. Pickl, Jason Gotlib, Hans-Peter Horny, Andreas Reiter, Gerlinde Mitterbauer-Hohendanner, Giulio Superti-Furga, Peter Valent, Karoline V. Gleixner, Matthias Mayerhofer, Sabine Cerny-Reiterer, Gregor Hörmann, Uwe Rix, Keiryn L. Bennett, Emir Hadzijusufovic, KIT-D816V–independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib Blood. ,vol. 118, pp. 1885- 1898 ,(2011) , 10.1182/BLOOD-2010-06-289959

Marcello Guarino, Src signaling in cancer invasion. Journal of Cellular Physiology. ,vol. 223, pp. 14- 26 ,(2009) , 10.1002/JCP.22011

John H. Strickler, Shannon McCall, Andrew B. Nixon, John C. Brady, Herbert Pang, Christel Rushing, Allen Cohn, Alexander Starodub, Christy Arrowood, Sherri Haley, Kellen L. Meadows, Michael A. Morse, Hope E. Uronis, Gerard C. Blobe, S. David Hsu, S. Yousuf Zafar, Herbert I. Hurwitz, Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer Investigational New Drugs. ,vol. 32, pp. 330- 339 ,(2014) , 10.1007/S10637-013-0042-9

Richard S. Finn, Judy Dering, Charles Ginther, Cindy A. Wilson, Padraic Glaspy, Nishan Tchekmedyian, Dennis J. Slamon, Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Research and Treatment. ,vol. 105, pp. 319- 326 ,(2007) , 10.1007/S10549-006-9463-X

Yan Song, Xin Sun, Wei-Liang Bai, Wen-Yue Ji, Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro European Archives of Oto-rhino-laryngology. ,vol. 270, pp. 1397- 1404 ,(2013) , 10.1007/S00405-013-2394-3

Sarah J Parsons, J Thomas Parsons, Src family kinases, key regulators of signal transduction Oncogene. ,vol. 23, pp. 7906- 7909 ,(2004) , 10.1038/SJ.ONC.1208160